Insider Selling: Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $41,514.06 in Stock

Kezar Life Sciences, Inc. (NASDAQ:KZRGet Rating) major shareholder Morningside Venture Investment sold 6,114 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $6.79, for a total transaction of $41,514.06. Following the completion of the sale, the insider now owns 5,872,993 shares of the company’s stock, valued at approximately $39,877,622.47. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Morningside Venture Investment also recently made the following trade(s):

  • On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total transaction of $33,850.00.
  • On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.97, for a total transaction of $84,769.14.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $6.42 on Friday. The company has a current ratio of 31.15, a quick ratio of 31.15 and a debt-to-equity ratio of 0.03. The firm has a market cap of $438.99 million, a PE ratio of -6.36 and a beta of 0.23. Kezar Life Sciences, Inc. has a 12 month low of $4.30 and a 12 month high of $18.55. The stock has a fifty day moving average price of $7.06 and a 200-day moving average price of $8.35.

Kezar Life Sciences (NASDAQ:KZRGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities research analysts predict that Kezar Life Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wells Fargo & Company decreased their target price on Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, January 3rd.

Institutional Investors Weigh In On Kezar Life Sciences

Large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in Kezar Life Sciences by 14.7% in the 3rd quarter. BlackRock Inc. now owns 4,104,929 shares of the company’s stock valued at $35,343,000 after acquiring an additional 525,139 shares during the period. State Street Corp lifted its stake in Kezar Life Sciences by 381.3% in the 3rd quarter. State Street Corp now owns 3,537,701 shares of the company’s stock valued at $30,460,000 after buying an additional 2,802,611 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Kezar Life Sciences by 22.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,993,207 shares of the company’s stock worth $25,771,000 after buying an additional 556,020 shares during the last quarter. Victory Capital Management Inc. increased its stake in Kezar Life Sciences by 58.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,770,098 shares of the company’s stock worth $22,909,000 after buying an additional 1,017,391 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $11,735,000. 84.03% of the stock is owned by hedge funds and other institutional investors.

About Kezar Life Sciences

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

See Also

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.